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A B S T R A C T
Superoxide generation by mitochondria respiratory complexes is a major source of reactive oxygen species (ROS)
which are capable of initiating redox signaling and oxidative damage. Current understanding of the role of
mitochondrial ROS in health and disease has been limited by the lack of experimental strategies to selectively
induce mitochondrial superoxide production. The recently-developed mitochondria-targeted redox cycler
MitoParaquat (MitoPQ) overcomes this limitation, and has proven effective in vitro and in Drosophila. Here we
present an in vivo study of MitoPQ in the vertebrate zebrafish model in the context of Parkinson's disease (PD),
and in a human cell model of Huntington's disease (HD). We show that MitoPQ is 100-fold more potent than non-
targeted paraquat in both cells and in zebrafish in vivo. Treatment with MitoPQ induced a parkinsonian phe-
notype in zebrafish larvae, with decreased sensorimotor reflexes, spontaneous movement and brain tyrosine
hydroxylase (TH) levels, without detectable effects on heart rate or atrioventricular coordination. Motor phe-
notypes and TH levels were partly rescued with antioxidant or monoaminergic potentiation strategies. In a HD
cell model, MitoPQ promoted mutant huntingtin aggregation without increasing cell death, contrasting with the
complex I inhibitor rotenone that increased death in cells expressing either wild-type or mutant huntingtin.
These results show that MitoPQ is a valuable tool for cellular and in vivo studies of the role of mitochondrial
superoxide generation in redox biology, and as a trigger or co-stressor to model metabolic and neurodegen-
erative disease phenotypes.
1. Introduction
Reactive oxygen species (ROS) were originally characterized as cell-
damaging by-products of biological reactions. There is now compelling
evidence that ROS also participate in physiological signaling, regulating
redox-dependent switches in proteins that govern proliferation, meta-
bolism, gene transcription, inflammation and ageing [11,20,46]. Su-
peroxide produced by mitochondrial respiratory complexes is a major
source of ROS, involved in signaling to other cellular compartments and
in oxidative damage [1]. Available strategies to increase mitochondrial
superoxide include respiratory complex inhibitors, which disturb the
membrane potential and ATP synthesis [30], and non-targeted redox
cyclers, which lead to substantial superoxide production outside
mitochondria [6], thereby confounding data interpretation. Thus, the
current understanding of the pathophysiological role of mitochondrial
superoxide has been limited by the lack of strategies to selectively in-
crease its generation in cells and in vivo [20].
MitoParaquat (MitoPQ) is a recently developed molecule com-
prising the redox cycler paraquat conjugated to a mitochondria-tar-
geting triphenylphosphonium lipophilic cation. MitoPQ accumulates in
energized mitochondria and produces superoxide by redox cycling at
complex I. It was previously shown in vitro that MitoPQ increases mi-
tochondrial superoxide production in cells, and disturbs cardiac func-
tion in the isolated perfused mouse heart [41]. There is currently lim-
ited information on the in vivo effects of MitoPQ, particularly in disease
models. In vivo, MitoPQ was previously tested only in flies (Drosophila
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melanogaster), where it was found to reduce lifespan, without further
functional or behavioral analyses [41]. Here we have performed the
first in vivo characterization of the effects of MitoPQ in a vertebrate
model, the zebrafish (Danio rerio). We also assessed the usefulness of
MitoPQ in the context of neurodegenerative disease modeling in cells.
Zebrafish is well-suited for in vivo drug screening given its ad-
vantages, including larval transparency (allowing non-invasive studies
of cardiac function), reduced size (facilitating behavioral evaluation),
and high genetic and physiological homology to mammals [48]. The
zebrafish is increasingly used to study neurodegenerative disorders
[35,50] and associated processes such as mitochondrial dysfunction
[2,36] and oxidative stress [14,15,27,29].
Here we investigate in vivo mitochondrial superoxide generation by
MitoPQ in zebrafish. Complementing prior evidence that MitoPQ se-
lectively generates superoxide within mitochondria [41], we show here
the higher potency of MitoPQ vs. paraquat in cells and in zebrafish. We
further show that MitoPQ induces a parkinsonian phenotype in zebra-
fish, with decreased spontaneous movement and brain tyrosine hy-
droxylase levels. We also tested MitoPQ in a Huntington's disease cel-
lular model where it increased mutant huntingtin (mHtt) aggregation.
These results support MitoPQ as a useful tool for investigating super-
oxide production in pathology in animal and cell models of disease.
2. Material and methods
2.1. Drugs, solvents and solutions
MitoPQ was synthesised as previously described [41]. Culture
media and supplements were from Gibco. Paraquat, N-acetyl-L-cysteine
(NAC), desipramine, rotenone, myxothiazol, antimycin A, oligomycin
B, and all other drugs or reagents were from Sigma-Aldrich, unless
otherwise stated. MitoPQ, rotenone and oligomycin stock solutions
were prepared in dimethyl sulfoxide (DMSO), whereas those from de-
sipramine, paraquat, and NAC were prepared in water. Myxothiazol
and antimycin stock solutions were prepared in methanol. Experiments
in zebrafish larvae were performed with 0.1–0.5% DMSO. Experiments
in U2OS cells were performed in presence of 0.1–0.5% DMSO or 0.1%
methanol. Control treatment conditions contained the same amount of
solvent (DMSO or methanol) as the respective drug treatment condi-
tions.
2.2. Zebrafish maintenance and drug treatments
Adult wild-type zebrafish (Danio rerio) or larvae were maintained at
28 ± 1 °C with 14 h:10 h light:dark cycles and handled for egg pro-
duction as we previously described [35,36]. Fertilized eggs were kept in
autoclaved water containing 1 µM methylene blue until 3 days post
fertilization (dpf). At 3 dpf, hatched larvae without detectable ab-
normalities were randomly distributed into multi-well plates, con-
taining autoclaved water and exposed to treatments (MitoPQ, paraquat,
NAC, desipramine, or solvent). In all experiments, larvae were imaged
daily with a stereomicroscope to assess viability. Dead larvae were re-
moved, and half volume was replaced with freshly prepared treatment
solutions [35]. For survival and movement experiments, larvae were
exposed to drugs in 24-well plates (5 larvae/500 µL/well), while to
assess cardiovascular function, larvae were exposed to drugs in 96-well
plates (1 larvae/200 µL/well). In population assays, such as quantifi-
cation of adenosine nucleotides and dot-blot, as well as for immuno-
fluorescence, larvae were exposed to drugs in 12-well plates (15–30
larvae/1mL/well).
2.2.1. Cardiovascular function
At 5 and 6 dpf, larvae were anaesthetized with 0.8M tricaine me-
thanesulfonate and their heartbeats recorded for 30 s, at 10x magnifi-
cation in a customised Nikon-Prior-Hamamatsu (NPH) Imaging System,
composed by an inverted microscope (Eclipse TE300, Nikon), a
motorized stage (ProScan, Prior), a CCD camera (ORCA-ER,
Hamamatsu), and a monochromator (Polychrome II, Photonics), all
controlled by the open source software Micro-Manager (v. 2.0; https://
micro-manager.org). Videos were captured at 30 frames per second
(fps) and processed with ImageJ (https://imagej.nih.gov/ij/) for as-
sessing atrioventricular coordination and heart rate.
2.2.2. Adenine nucleotides and energy charge
Nucleotide extraction was performed at 5 and 6 dpf, as we pre-
viously described [35], but now using a Precellys 24 homogenizer
(Bertin Technologies) at 6800 rpm (3×20 s, CK28 beads). ATP, ADP
and AMP were quantified using HPLC (reversed-phase column;
250×4.6mm Luna 5 µm C18(2) 100 Å; Phenomenex) with a diode-
array detector (Agilent 1100 series), measuring 260 nm absorbance.
Energy charge was calculated with the formula: ([ATP]+0.5[ADP]) ÷
([ATP]+[ADP]+[AMP]) [49].
2.2.3. Behavioral evaluation
Measurements of spontaneous swimming and sensorimotor reflexes
were performed at 5 dpf, as we previously described [35]. Briefly, in-
dividual larvae in 6-well plates were recorded for 10min at 28 ± 1 °C
with a HD digital camera (C525, Logitech). Videos were processed with
iWisoft (www.iwisoft.com/videoconverter) and ImageJ to extract time
and spatial coordinates. Calculations were automated in customised
spreadsheets (Excel, Microsoft) to derive movement parameters: dis-
tance (cm), movement speed (distance ÷ time in movement; mm/s), and
initiations. After the spontaneous swimming, each larva was tested for
reflexes by gently touching with a micropipette tip in the head and in
the tail. Immediate swimming after touch was scored as a positive re-
sponse. Head and tail touches were alternated, spaced by 30 s, and the
procedure repeated 10 times for each larva.
2.2.4. Quantification of protein carbonyl groups
Protein extraction was performed at 5 dpf by sonication of 45 larvae
in ice-cold lysis buffer (250mM sucrose; 20mM HEPES; 3mM EDTA,
pH=7.5) supplemented with a protease inhibitor cocktail (Fisher
Scientific). After 3 freeze-thaw cycles, lysates were centrifuged at
300×g (10min, 4 °C) and carbonyls quantified in the supernatant.
Protein was quantified according to Bradford method and carbonyl
derivatization was performed as previously described [25], with minor
modifications. Briefly, 200 µL of protein extract containing 20 µg pro-
tein were incubated with 200 µL of 12% sodium dodecyl sulfate and
400 µL of 20mM 2,4-dinitrophenylhydrazine hydrochloride (TCI
Europe) for 30min in the dark. After neutralization with 300 µL of 2M
Tris with 18% β-mercaptoethanol, samples containing 1 µg of protein
were spotted on a nitrocellulose membrane (Bio-Dot Microfiltration
Apparatus, Bio-Rad). Membranes were blocked for 1 h with 5% bovine
serum albumin in PBST (phosphate buffer solution with 0.05% Tween
20), and incubated with anti-dinitrophenol antibody (MAB2223,
1:1000, Sigma-Aldrich; 1 h). After washing with PBST, membranes
were incubated with secondary antibody (G-21040, 1:4000; Life
Technologies; 1 h), and imaged using a Chemiluminescent kit (Novex
ECL, Life Technologies) and a ChemiDoc MP (Bio-Rad). Coomassie
staining was used for loading control. Densitometric analyses were
performed with Image J.
2.2.5. Immunofluorescence
At 5 dpf, larvae were fixed (4% paraformaldehyde, overnight at
4 °C) and processed for immunofluorescence as we previously described
[35]. Primary antibodies: anti-acetylated-α-tubulin (T6793, Sigma-Al-
drich; 1:1000) or anti-tyrosine hydroxylase (TH) (MAB318, Merck
Millipore; 1:500) overnight at 4 °C. Secondary antibody: anti-mouse
AlexaFluor-488 (A-11029, Life Technologies) overnight at 4 °C. Larvae
mounted in Glycergel medium (DAKO) were imaged in the aforemen-
tioned NPH Imaging System. For intensity comparisons, non-saturated
images were acquired with identical equipment settings. The mean
B.R. Pinho et al. Free Radical Biology and Medicine 130 (2019) 318–327
319
intensity of immunofluorescence was quantified after background
subtraction using ImageJ.
2.3. U2OS cell maintenance
Human U2OS cells have been previously used to study mHtt ag-
gregation [4]. These cells are advantageous for their high transfection
efficiencies, and also for imaging studies (large, flat cells with clearly-
defined nuclear and cytosolic compartments), explaining their wide-
spread use, including in neurodegenerative disease contexts [3,4,40].
Here, U2OS cells (ATCC) were cultured in either glucose media (gly-
colytic conditions) or galactose media (oxidative phosphorylation –
OXPHOS – dependent conditions). Glucose media was composed by
Dulbecco's Modified Eagle's Medium (DMEM) with low glucose sup-
plemented with 10% foetal bovine serum (FBS) and penicillin/strep-
tomycin. Galactose media was composed by DMEM without glucose
supplemented with 10mM galactose, 2 mM glutamine, 5mM HEPES,
1mM sodium pyruvate, 10% FBS, and penicillin/streptomycin. Cells
were maintained at 37 °C, in humidified air with 5% CO2.
2.3.1. Resazurin metabolism
U2OS cells were seeded at 2.0×105 cells/mL in 96-well plates
(200 µL/ well). After 24 h, cells were treated with drugs (MitoPQ,
paraquat, rotenone, oligomycin, myxothiazol, or antimycin) or solvents
(DMSO or methanol). After 20 h of treatment, 40 µM resazurin was
added to the cells and its reduction to resorufin assessed by fluorescence
readings (Synergy HT, BioTek; 530 nm excitation and 590 nm emis-
sion). Readings were performed at 30min intervals during 4 h (com-
pleting 24 h of treatment).
2.3.2. Huntington's disease cell model
U2OS cells in OXPHOS-dependent conditions (galactose media)
were seeded at 1.5×105 cell/mL in 8-well glass-bottom µ-slides
(80827, Ibidi), and transfected as we previously described [17]. For
transfection with EGFP-Httex1Q23 or EGFP-Httex1Q74 (40261 and
40262, Addgene), cells were treated with Opti-MEM, containing 0.5 µg
plasmid DNA, 0.5 µL Lipofectamine LTX and 0.5 µL Plus reagent (In-
vitrogen) for 45min (37 °C, 5% CO2). 16 h after transfection, cells were
treated with 30 µM MitoPQ, 1 µM rotenone or solvent (0.3% DMSO).
Nucleus staining with Hoechst 34580 (1 µg/mL, 30min) and imaging
was performed 24 h after treatment. EGFP-Huntingtin (Htt) was excited
at 488 nm and Hoechst at 380 nm in the NPH Imaging System. Trans-
fected cells were scored as live or dead through analysis of cell (bright
field images) and nuclear (Hoechst staining) morphologies: shrunken
cells with condensed DNA were considered dead. Live cells were further
divided as having a diffuse or aggregated Htt profile.
2.3.3. Mitochondrial membrane potential and complex analysis
Transfected U2OS cells were equilibrated for 30min at 37 °C with
50 nM TMRM+ (quench mode) in culture media and imaged with the
NPH Imaging System. Inhibition of mitochondrial complexes was per-
formed with oligomycin (6 µM; complex V), followed by rotenone
(2 µM, complex I), and antimycin A (2 µM, complex III). Uncoupler
(CCCP 2 µM) was added at the end of the experiment. EGFP-Htt ex-
pressing cells were identified with 488 nm excitation, and time-lapse
imaging for changes in TMRM+fluorescence was performed at 30 s
intervals with 557 nm excitation. Forward ATP synthase operation was
detected by increased TMRM+ quenching (hyperpolarization) with
oligomycin, whereas complex I/III inhibition or CCCP uncoupling was
detected by TMRM+ dequenching (depolarization) [32,33].
2.4. Statistical analysis
Data are shown as mean ± standard error of the mean (SEM) of the
n number indicated in Figure legends, except for zebrafish survival data
that are shown as Kaplan-Meier representations. Data from zebrafish
larvae are from at least 3 different breedings. Concentration-response
curves were fitted with non-linear regression. Global differences
Fig. 1. Drug effects on cell metabolism and zebrafish survival. (A) Resazurin metabolism of U2OS cells grown in glucose media (glycolytic conditions) and galactose
media (OXPHOS-dependent conditions), after 24 h of treatment with increasing concentration of mitochondrial inhibitors: (i) rotenone – complex I inhibitor, (ii and
iii) myxothiazol and antimycin – complex III inhibitors; and (iv) oligomycin – ATP synthase inhibitor; n=3–4 independent experiments. (B) Resazurin metabolism of
U2OS cells in glucose versus galactose media after treatment with MitoPQ and paraquat (left); and their chemical structures (right). Note that the decyl triphe-
nylphosphonium lipophilic cation moiety targets MitoPQ to polarized mitochondria, and that MitoPQ was 100-fold more potent than paraquat in galactose media;
n=3 independent experiments, * P < 0.05. (C) Kaplan-Meier survival analysis of zebrafish larvae exposed to MitoPQ (i), paraquat (ii), or solvent (control),
n=24–50 larvae; and respective median survival times (iii).
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between two curves were tested with the sum-of-squares F test. For
normally distributed data, we used the Student's t-test when comparing
two groups, and the general linear model with Dunnet's post-Hoc when
comparing two or more groups to a control group. For non-normally
distributed data, we used the Kruskal-Wallis test with Dunn's post-Hoc
for one factor analysis, and the generalized linear model for multi-
factorial analyses. Data analyses were performed with Prism 6.0
(GraphPad) or SPSS Statistics version 25 (IBM).
3. Results and discussion
3.1. MitoPQ activity is mitochondria-dependent and 100-fold more potent
than paraquat
MitoPQ was previously shown to induce selective mitochondrial
superoxide production in cells [41]. To extend those data, here we
tested the mitochondrial-dependency of MitoPQ toxicity in assays with
U2OS cells grown in glucose media versus galactose media. The ga-
lactose media composition (glucose-free) limits glycolysis and increases
the cellular dependency on mitochondria (OXPHOS-dependent condi-
tions) [10]. This is evidenced by data in Fig. 1, where mitochondria
inhibitors with different targets were all found to induce a much more
pronounced inhibition of resazurin metabolism in cells in galactose
media (Fig. 1Ai-iv). In agreement with a mitochondria-dependent ac-
tivity, MitoPQ was significantly more potent in OXPHOS-dependent
than in glycolytic conditions (Fig. 1B). In contrast, non-targeted para-
quat showed no significant difference in potency between conditions
(Fig. 1B). Moreover, MitoPQ was 100-fold more potent than paraquat:
10 μM MitoPQ induced comparable effects to 1mM paraquat (Fig. 1B).
This difference in potency is consistent with previous data comparing
the hydrogen peroxide production induced by MitoPQ vs. paraquat
from isolated heart mitochondria [41].
We next performed in vivo testing of MitoPQ in a vertebrate model.
MitoPQ-treated zebrafish presented increased hydroethidine (dihy-
droethidium; DHE) oxidation, indicating increased intracellular oxidant
formation [55] (Supplementary Fig. 1). Kaplan-Meier analysis of zeb-
rafish larvae continuously exposed to MitoPQ or paraquat from 3 to
8 dpf revealed that both compounds induced time- and concentration-
dependent effects on survival (Fig. 1Ci,ii). In agreement with the data
from U2OS cells, MitoPQ was 100-fold more potent that paraquat in
zebrafish (Fig. 1Ciii). Taken together, these results are consistent with
the mitochondrial accumulation of MitoPQ driven by its lipophilic ca-
tion moiety (Fig. 1B; [41]), explaining both its mitochondrial-depen-
dent effects and its higher potency than paraquat.
3.2. MitoPQ induces a parkinsonian phenotype in zebrafish
To characterize the in vivo phenotypes induced by MitoPQ in zeb-
rafish, we first monitored its effects upon sensorimotor reflexes and
spontaneous swimming. Larvae treated for 48 h (3–5 dpf) with MitoPQ
Fig. 2. Behavioral, functional and biochemical parameters in zebrafish treated with MitoPQ vs. Paraquat. Zebrafish were treated with the indicated concentrations of
MitoPQ and paraquat, or solvent (control), from 3 dpf until measurements (at 5 or 6 dpf). (A, B) Sensorimotor reflexes and spontaneous movement at 5 dpf: (Ai) tail
and (Aii) head reflexes; (Bi) representative trajectories; (Bii) distance; (Biii) initiations, and (Biv) movement speed; n=27–78 larvae; *P < 0.05 vs. control. (C)
Protein carbonyl groups measured by dot-blot at 5 dpf. n=3 independent experiments, *P < 0.05 vs. control. (D) Left – energy charge values, calculated with the
indicated formula, at 5 dpf (triangles) and 6 dpf (circles); Right – representative HPLC chromatogram with adenine nucleotides; n=3–4 independent experiments.
(E) Heart rate and atrioventricular coordination at 6 dpf; n=16–19 larvae.
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(1–10 µM) or paraquat (10–1000 µM) showed a concentration-depen-
dent reduction in escape responses evoked by either tail- or head-touch
stimulation (Fig. 2A). These results indicate an impairment in evoked
sensorimotor reflexes for both compounds, with 10 μM MitoPQ again
presenting similar effects to 1mM paraquat. Interestingly, when com-
paring effects on spontaneous movement, MitoPQ but not paraquat
reduced the travelled distance and the number of initiations of move-
ment, without altering movement speed (Fig. 2B). To further in-
vestigate the in vivo effects of MitoPQ we studied additional biochem-
ical and functional parameters, comparing 10 μM MitoPQ with 1mM
paraquat.
Treatment with MitoPQ (3–5 dpf) induced a significantly higher
protein carbonyl content in zebrafish larvae than paraquat (Fig. 2C),
which indicates a higher level of oxidative damage that contributes to
the reduced spontaneous movement with MitoPQ, but not paraquat
(Fig. 2B). To investigate if differences in energy availability might ex-
plain the reduced movement with MitoPQ we measured adenine
nucleotide levels and calculated the energy charge. Treatment with
either MitoPQ or paraquat from 3 to 5 dpf evoked no detectable
changes in energy charge, although extending treatment to 6 dpf did
significantly decrease the energy charge (Fig. 2D). This is a likely
consequence of cumulative toxicity, together with the time-dependent
depletion of yolk reserves that facilitates detection of drug-induced
metabolic dysfunction.
We next tested if treatment with MitoPQ or paraquat affected zeb-
rafish heart function, but neither treatment changed heart rate nor at-
rioventricular coordination, even when extended to 6 dpf (Fig. 2E). This
lack of effect upon the zebrafish heart rate is compatible with previous
data from the isolated mouse heart, where direct exposure to MitoPQ
did not change the heart rate, in spite of disturbing diastolic pressures
and coronary flow [41]. Here we cannot exclude the possibility that
MitoPQ disturbs pressure and flow of the zebrafish heart (which has a
single atria and ventricle), but our imaging method allows detection of
changes in atrioventricular coordination induced by mitochondrial
Fig. 3. Brain levels of acetylated-α-tubulin and tyrosine hydroxylase (TH) in zebrafish treated with MitoPQ vs. paraquat. Larvae were treated from 3 to 5 dpf with
10 µM MitoPQ, 1mM paraquat, or solvent (control). Acetylated-α-tubulin and TH were quantified by immunofluorescence at 5 dpf. (A) Representative images and
quantification of acetylated-α-tubulin in the midbrain; n=7–11 larvae, *P < 0.05 vs. control. (B) Representative images of TH-positive neurons and quantification
of TH levels in (i) the pretectum, (ii) middle diencephalon and (iii) hypothalamus. The first column shows global TH staining in blue, with a yellow highlight for the
region under analysis; n=16–18 larvae, *P < 0.05 vs. control.
B.R. Pinho et al. Free Radical Biology and Medicine 130 (2019) 318–327
322
inhibitors [36] and such changes were not found in the MitoPQ-treated
zebrafish. Thus, the reduced movement phenotype in MitoPQ-treated
larvae at 5 dpf is unlikely to result from a widespread collapse of energy
availability (preserved energy charge in whole-organism measure-
ments) nor from generalized muscular impairment (preserved heart
rate and coordination). Nevertheless, there could still be major meta-
bolic changes taking place in vulnerable tissues, which prompted us to
investigate if MitoPQ was compromising neuronal activity.
Using tubulin acetylation levels as an indicator of neuronal structure
and function, we found significant decreases in labelling in the mid-
brain region with either MitoPQ or paraquat treatment, (Fig. 3A),
which is compatible with both compounds impairing sensorimotor re-
flexes. Using tyrosine hydroxylase (TH) levels as a marker for dopa-
minergic neuronal clusters [43], we found that MitoPQ, but not para-
quat, significantly decreased brain TH levels, particularly in the
pretectum and middle diencephalon (Fig. 3B). These two neuronal
clusters express the dopamine transporter [21] and are the most af-
fected in zebrafish exposed to the dopaminergic toxin MPP+ [43].
Thus, the differential impact of MitoPQ and paraquat upon these neu-
ronal clusters could explain their differential effects upon spontaneous
movement.
These results show that MitoPQ induces in vivo oxidative damage
(increased protein carbonyl content) and a parkinsonian phenotype in
zebrafish, particularly the reduced mobility and decreased brain levels
of tyrosine hydroxylase that are common features of Parkinson's Disease
(PD) [22]. These phenotypes suggest that the mitochondrial superoxide
production induced by MitoPQ impairs dopaminergic neurotransmis-
sion. This is in agreement with dopaminergic neurons being highly
vulnerable to oxidative stress [52,54], and with PD patients presenting
oxidative stress markers and monoaminergic dysregulation [13,28,31].
3.3. Rescue of MitoPQ-induced phenotypes with antioxidant or
monoaminergic potentiation strategies
Given the pro-oxidant properties of MitoPQ and the sensorimotor
phenotypes associated with reduced TH (a key enzyme in the synthesis
of dopamine and other monoamine neurotransmitters), we tested if
these phenotypes could be rescued with antioxidant or monoaminergic
potentiation strategies. For this purpose, we used the antioxidant N-
acetyl-L-cystein (NAC; [44]) and desipramine – an inhibitor of the
Fig. 4. Effects of N-acetyl-L-cystein and desipramine on the behavioral and neurochemical phenotypes of MitoPQ-treated larvae. Larvae were treated from 3 to 5 dpf
with solvent (control), 10 µM MitoPQ, 1mM N-acetyl-L-cystein (NAC), or 10 µM desipramine, alone or in the indicated combinations. (A) Sensorimotor reflexes at
5 dpf; (B) Spontaneous swimming distances at 5 dpf; n=19–54 larvae. (C) Representative acetylated-α-tubulin immunofluorescence in the midbrain and its
quantification; n=7–11 larvae. (D) Representative tyrosine hydroxylase immunofluorescence showing neuronal clusters in the pretectum and associated quanti-
fications; n=13–18 larvae. *P < 0.05 vs. control; #P < 0.05 vs. MitoPQ.
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reuptake of monoamine neurotransmitters [9]. We selected the con-
centrations of 1mM NAC and 10 µM desipramine based on previous
determination of efficacy [26,34,42,44], and lack of effect on zebrafish
survival under our experimental conditions (Supplementary Fig. 2).
NAC or desipramine alone, from 3 to 5 dpf, had no effect on zeb-
rafish sensorimotor reflexes, but in co-treatment with MitoPQ they
significantly rescued the impairment of head or tail touch responses by
MitoPQ (Fig. 4A). NAC alone evoked no changes in spontaneous
movement, whereas desipramine alone significantly decreased the
swimming distance (Fig. 4B). We therefore focused on co-treatment
with NAC and found that it significantly attenuated the spontaneous
movement impairment evoked by MitoPQ (Fig. 4B). We next tested if
this movement recovery correlated with neurochemical changes. Al-
though NAC co-treatment failed to significantly recover alpha-tubulin
acetylation in the midbrain (Fig. 4C), it significantly increased TH le-
vels in the pretectum (Fig. 4D) – the region showing the largest de-
crease evoked by MitoPQ (Fig. 3B). Mechanistically, the superoxide
generated by MitoPQ is rapidly converted to hydrogen peroxide, which
crosses mitochondrial membranes and generates other reactive species
that induce widespread oxidative damage [30,46,53]. NAC may quench
Fig. 5. Effects of MitoPQ on huntingtin proteostasis and cell viability in a HD cell model. U2OS cells transfected with GFP-Httex1Q23 or GFP-Httex1Q74 were treated
for 24 h with 30 µM MitoPQ, 1 µM rotenone, or solvent (control). (A) Huntingtin expression (EGFP) and nucleus staining (Hoechst 34580). Representative images
show cells with Htt in diffuse form (Q23 and Q74) and Htt aggregates (observed only with Q74). (B) Quantification of live cells presenting (i) only diffuse huntingtin
or (ii) containing aggregates; and (iii) cell death. n=6 independent experiments, * P < 0.05 vs. Q23; #P < 0.05 vs. Q74.
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this widespread damage by being a source of sulfhydryl groups that
scavenge free radicals and protect protein disulfide bonds [12,44].
These results show that the Parkinson's like phenotypes induced by
MitoPQ in zebrafish can be partially ameliorated by the indicated
pharmacological strategies (antioxidant and monoaminergic potentia-
tion), highlighting the potential of MitoPQ as a tool for in vivo redox
biology research. We next decided to test MitoPQ in another experi-
mental model of disease.
3.4. MitoPQ increases huntingtin aggregation in a cell model of Huntington's
disease
Given that treatment with MitoPQ generated a parkinsonian phe-
notype in zebrafish, which may also be interpreted as accelerated
ageing [7], we decided to test how treatment with MitoPQ affects
survival of a cell model of Huntington's disease (HD) and the proteos-
tasis of the disease associated protein – huntingtin (Htt). As with PD,
HD pathophysiology includes mitochondrial dysfunction [18] and age-
dependent neurodegeneration [24]. HD progresses with increased for-
mation of mutant Htt aggregates that evoke a slow, necrotic death [39].
To model HD, we used U2OS cells expressing GFP-tagged wild-type
(Q23) or mutant (Q74) Htt constructs, in OXPHOS-dependent condi-
tions (galactose media), and treated with MitoPQ for 24 h. Solvent
alone and rotenone were used for comparison with the effects of
MitoPQ. Concentrations of 30 µM MitoPQ and 1 µM rotenone produced
similar effects on metabolism in OXPHOS-dependent conditions
(Fig. 1A vs. C). Under control conditions, cells expressing Q23-Htt
showed a diffuse GFP distribution with no detectable aggregates
(Fig. 5A). In contrast, cells expressing Q74-Htt showed aggregates and a
significantly higher cell death than Q23-Htt cells (Fig. 5B). Treatment
with MitoPQ increased Q74-Htt aggregation without increasing cell
death in cells expressing Q23- or Q74-Htt. This differs from treatment
with rotenone where we observed a significant increase in cell death,
particularly in cells expressing Q23-Htt.
How might MitoPQ promote mHtt aggregation? While H2O2 diffu-
sion from MitoPQ-challenged mitochondria might modify mHtt di-
rectly, promoting its aggregation [23], particularly near mitochondria
(Fig. 6A), there is currently more evidence for indirect effects of ROS via
impairments in the proteostasis machinery (Fig. 6C). Oxidative stress
was found to promote mHtt aggregation in association with protea-
somal dysfunction [16] and, particularly, mitochondria-derived ROS
was found to reduce the activity of the ubiquitin-proteasome system
[45,8]. Additionally, mitochondria-derived ROS might promote mHtt
aggregation by compromising the activity of molecular chaperones,
which are vulnerable to ROS-mediated oxidation [47].
These results indicate that the use of MitoPQ as a co-stressor, to
accelerate disease phenotypes, has advantages over classical mi-
tochondrial inhibitors such as rotenone, namely by avoiding cell death
under control conditions. Further, these results suggest that MitoPQ is
an interesting tool to study the effects of increased mitochondrial su-
peroxide production on huntingtin proteostasis, and possibly that of
other mutant proteins in disease models.
It is important to note that neurodegenerative disorders are asso-
ciated with decreased mitochondrial membrane potential [5]. Since
MitoPQ uptake into mitochondria depends on mitochondrial membrane
potential, it may be more useful in models of early stage disease where
mitochondrial membrane potential is still maintained at normal levels.
In our experimental conditions, at the time of treating with MitoPQ,
cells expressing either diffuse or aggregated mHtt retained mitochon-
drial membrane potential (TMRM+ staining) and were net ATP gen-
erators (oligomycin hyperpolarization) (Fig. 6B). As with other drugs or
probes influenced by mitochondrial membrane potential [37], the
Fig. 6. Mitochondria and ROS-medi-
ated impairment of huntingtin proteos-
tasis. (A) Representative U2OS cells ex-
pressing diffuse (left) and aggregated
(right) mHtt-EGFP (green) in proximity
of TMRM+-stained mitochondria (red).
(B) Representative tracings of changes
in TMRM+ fluorescence of U2OS cells
exposed to the indicated drugs: O, 6 µM
oligomycin; R, 2 µM rotenone; A, 2 µM
antimycin A; C, 2 µM CCCP; (i) non-
transfected cell; (ii) cell expressing
mHtt-EGFP, 24 h-post transfection; tra-
cings are representative of at least 10
cells per condition. (C) Mitoparaquat
promotes mitochondria superoxide for-
mation [41], arguably accelerating a
process that is also thought to occur in
the presence of mutant huntingtin
(mHtt; [38,51]). Mitochondria-derived
reactive-oxygen species (ROS) impair
the ubiquitin-proteasome system
[16,45,8], and may also impair chaper-
ones [23,47], limiting mHtt degradation
and thereby promoting its accumulation
and aggregation. Increased levels of
mHtt promote its interaction with mi-
tochondria, and ROS formation [38,51].
Such ROS, together with those gener-
ated from mHtt aggregation [19] may
modify mHtt directly, further promoting
its aggregation [23]. (For interpretation
of the references to color in this figure
legend, the reader is referred to the web
version of this article).
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mitochondrial polarization status should thus be taken into considera-
tion when using MitoPQ.
4. Conclusions
The generation of mitochondrial superoxide plays an important role
in ROS signaling and oxidative damage, but the lack of strategies for its
selective generation have limited advancement in this field of research.
The mitochondrial superoxide generator MitoPQ was recently devel-
oped as a tool to overcome this limitation, and here we present its first
in vivo study in a vertebrate model. MitoPQ induces a parkinsonian
phenotype in zebrafish larvae, supporting a contribution of mitochon-
drial superoxide generation to the development of PD. MitoPQ also led
to an increase in mutant huntingtin aggregation in a cell model. These
data suggest that MitoPQ can accelerate ageing-associated processes in
vivo and in cell models. MitoPQ is thus an interesting co-stressor to
accelerate disease phenotypes, and a valuable tool to investigate the
role of mitochondrial superoxide generation in physiological and pa-
thological processes, using cellular and in vivo models.
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